Anzeige
Mehr »
Dienstag, 21.07.2026 - Börsentäglich über 12.000 News
+50% in 13 Tagen - Steht der große Ausbruch jetzt bevor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
12:46Novartis Q2 profits recover as revenue mantle passes to newer medicines
12:46Bristol Myers, NVIDIA join forces to build life science's 'most powerful' AI factory
11:46EMA's CHMP grants PRIME status to AbelZeta's C-CAR168
10:46Halozyme and Incyte sign licence agreement for INCA033989 formulations
MoNovartis and Takeda drugs gain rare blood cancer routine use on NHS
MoSamsung Biologics to acquire PolyPeptide in $1.81bn cash deal
MoUK biotech financing continues recovery trajectory on five-year Q2 high
MoAptar unveils framework for injectable drug delivery systems
FrBayer's heart failure drug bound for NHS on NICE recommendation
FrFDA grants traditional approval to Novartis' Fabhalta for IgAN
FrMSD wins FDA approval for cholesterol pill to help plug Keytruda void
FrJCVI issues recommendation on adolescent MenB vaccination in UK
DoUK commits to pharma IP protection in Swiss trade deal
DoNovo secures European approval for oral Wegovy to extend lead over Lilly
DoLilly enters psychedelic realm through $2.8bn AtaiBeckley takeover
DoBig pharma-backed AdvanCell pockets $315m to progress RLT to Phase III
DoTelix opens radiopharmaceutical facility in Australia for cancer treatment
DoHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
MiJ&J raises FY26 outlook following positive Q2
MiWomen's health attracted record equity in 2025 as companies share capital
MiAAIC26: The role of biomarkers in primary care and early diagnostics
MiFDA grants priority review to Roche's Gazyva/Gazyvaro for pMN
MiInnovent licenses IBI355 rights to Spero for up to $1.1bn
14.07.AstraZeneca pays up to $1.5bn to license Dizal Pharma's lung cancer drug
14.07.Novartis and Chai Discovery collaborate on antibody identification